DIRECTOR, ELLIS FISCHEL CANCER CENTER & DIV. DIRECTOR (DIV. CHIEF), HEMATOLOGY & MEDICAL ONCOLOGY

Employer
University of Missouri Health Care
Location
Columbia, Missouri
Salary
-
Posted
Mar 23, 2021
Closes
Apr 22, 2021
Position
Director
Hours
Full Time

University of Missouri Health Care

DIRECTOR, ELLIS FISCHEL CANCER CENTER & DIVISION DIRECTOR (DIVISION CHIEF), HEMATOLOGY AND MEDICAL ONCOLOGY

University of Missouri Health Care is seeking an inspirational leader to serve as the Director of the Ellis Fischel Cancer Center (EFCC).  This individual will also serve as Division Director of Hematology and Medical Oncology. 

The Director, EFCC and Division Chief will have a dual reporting relationship to Dr. Steven Zweig, Dean of the MU School of Medicine, and to Dr. Kristin Hahn-Cover, Chair of the Department of Medicine.  This person will ensure that basic, translational and clinical research, as well as clinical activities grow, and exemplary fellowship training in Hematology and Oncology continues, as a consequence of their leadership in these two critical positions.

The University of Missouri in Columbia, Missouri is the state’s largest university and the flagship of the four-campus University of Missouri System. Founded in 1839, it was the first public university west of the Mississippi River.  It is a R1 member of the Association of American Universities with $278M in research funding.  Among the University’s research assets is the Research Reactor, the world's most powerful university research reactor and a sole source of several beta emitting isotopes used in nuclear medicine.

University of Missouri Health Care (MU Health Care) includes five hospitals and more than 60 primary and specialty-care clinics.  Among the best-known specialty hospitals is the Ellis Fischel Cancer Center (EFCC).  It was the first freestanding cancer center west of the Mississippi when constructed in 1938 as a 104-bed hospital.  The inpatient unit was moved to MU in 1990 and a new outpatient and research facility opened on campus in 2013.  The newly reimagined EFCC is an important platform for University strategies for clinical and research activity devoted to cancer.

One of the most advantageous features of the University of Missouri Columbia campus is the co-location of a medical school, a veterinary school and hospital, a school of arts and science, an engineering school, a school of agriculture, an extension program, a nuclear reactor, and a thriving health care system.  This offers tremendous opportunities for cross-campus collaboration that the University continues to leverage.

The University of Missouri’s NextGen Precision Health is a bold new program of discovery to serve and improve the lives of Missourians. A key element of this initiative will integrate and organize cancer research across its flagship campus in Columbia, facilitated by a new 265,000 sf. research facility (opening in October 2021), and new state support funding recruitment and program development.   The recent recruitment of Dr. Carolyn Anderson is an example of the success of the Initiative and how NGPH will catalyze cancer research.  Dr. Anderson leads the Molecular Imaging and Theranostics Center in developing targeted radiopharmaceutical therapy and molecular imaging agents for cancer and other diseases.

A top priority for this individual will be to grow clinical activities through recruitment, retention and development of additional faculty, and to expand the clinical trials portfolio. They will work collaboratively with Ellis Fischel’s many stakeholders to extend patient- and family-centered cancer care across organizational boundaries and to ensure that the operations of the Cancer Center as well as the Division of Hematology and Medical Oncology are mission, vision and values driven.

MU Health, inclusive of the EFCC and Department of Medicine, is prepared to provide significant support for recruiting additional faculty conducting clinical and translational cancer research. The next Director, EFCC and Division Chief will be in a position to significantly leverage the many areas of research excellence throughout the organization in these recruitments.

The ideal candidate is an accomplished program builder with a strong background in clinical oncology, and an experienced leader able to support and enhance the EFCC and Division's clinical, research and educational activities.  They will be recognized for accomplishments in research, patient care, leadership, and education.  The next Director, EFCC & Division Director will have demonstrated an ability to recruit and retain faculty and staff, and to lead and grow programs in a complex academic environment, ensuring that the academic and clinical activities of the Cancer Center continue to bring value to its many internal and external stakeholders, and distinction to MU Health. Qualified candidates possess an MD, DO, or MD/PhD degrees and are board certified in oncology, with dual certification in hematology desired.

All interested applicants are invited to send their curriculum vitae and letter of interest to the attention of Kristin Hahn-Cover, MD, FACP, Chair, Department of Medicine via email to Angie Simmons, Senior Associate at Korn Ferry at angie.simmons@kornferry.com.

The University will recruit and employ qualified personnel and will provide equal opportunities during employment without regard to race, color, religion, sex, sexual orientation, national origin, age, disability or status as a Vietnam-era veteran.

Apply for DIRECTOR, ELLIS FISCHEL CANCER CENTER & DIV. DIRECTOR (DIV. CHIEF), HEMATOLOGY & MEDICAL ONCOLOGY

Already uploaded your resume? Sign in to apply instantly

Apply

Upload from your computer

Or import from cloud storage

Your Resume must be a .doc, .pdf, .docx, .rtf, and no bigger than 1Mb


4000 characters left

When you apply for a job we will send your application to the named recruiter, who may contact you. By applying for a job listed on ASCO Career Center you agree to our terms and conditions and privacy policy. You should never be required to provide bank account details. If you are, please email us.